SMMT
Summit Therapeutics Inc.
Biotechnology
Market Cap$13.30B
5Y Perf.+134.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SMMT vs NUVL
Revenue, margins, valuation, and 5-year total return — side by side.
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.53B
5Y Perf.+461.1%
SMMT vs NUVL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SMMT | NUVL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $13.30B | $7.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-1.21B | $-450M |
| Total Debt | $21M | $0.00 |
| Cash & Equiv. | $225M | $262M |
SMMT vs NUVL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SMMT
NUVL
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Summit Therapeutics… (SMMT) | 100 | 234.0 | +134.0% |
| Nuvalent, Inc. (NUVL) | 100 | 561.1 | +461.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SMMT vs NUVL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NUVL leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SMMT
Summit Therapeutics Inc.
The Specific-Use Pick
In this particular matchup, SMMT is outpaced on most metrics by others in the set.
Best for: healthcare exposure
NUVL
Nuvalent, Inc.
The Income Pick
NUVL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.09
- EPS growth -48.9%
- 446.1% 10Y total return vs SMMT's 91.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 1.1% revenue growth vs SMMT's -402.6% |
| Stability / Safety | NUVL | Beta 1.09 vs SMMT's 1.89 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NUVL | +53.5% vs SMMT's -29.4% |
| Efficiency (ROA) | NUVL | -37.8% ROA vs SMMT's -243.1%, ROIC -32.5% vs -220.2% |
SMMT vs NUVL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
SMMT vs NUVL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVLLAGGINGSMMT
SMMTSummit Therapeutics I…
0leads
NUVLNuvalent, Inc.
5leads
6 Total Categories
CATEGORYLEADERvs SMMTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVL1/1
Valuation MetricsMultiples, price ratios, and targets
NUVL2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NUVL6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVL4/6
Risk & VolatilityBeta, volatility, and downside exposure
NUVL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUVL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SMMT and NUVL operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SMMTSummit Therapeuti… | NUVLNuvalent, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$1.0B | -$346M |
| Net IncomeAfter-tax profit | -$1.2B | -$450M |
| Free Cash FlowCash after capex | -$385M | -$313M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -166.7% | -17.8% |
NUVL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NUVL leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SMMTSummit Therapeuti… | NUVLNuvalent, Inc. |
|---|---|---|
| Market CapShares × price | $13.3B | $7.5B |
| Enterprise ValueMkt cap + debt − cash | $13.1B | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -11.91x | -17.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 19.46x | 5.96x |
| Price / FCFMarket cap ÷ FCF | — | — |
NUVL leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NUVL leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
NUVL delivers a -42.8% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-3 for SMMT.
| Metric | SMMTSummit Therapeuti… | NUVLNuvalent, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.9% | -42.8% |
| ROA (TTM)Return on assets | -2.4% | -37.8% |
| ROICReturn on invested capital | -2.2% | -32.5% |
| ROCEReturn on capital employed | -2.0% | -34.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$204M | -$262M |
| Cash & Equiv.Liquid assets | $225M | $262M |
| Total DebtShort + long-term debt | $21M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -26.85x |
NUVL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
NUVL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $54,613 today (with dividends reinvested), compared to $29,467 for SMMT. Over the past 12 months, NUVL leads with a +53.5% total return vs SMMT's -29.4%. The 3-year compound annual growth rate (CAGR) favors SMMT at 106.8% vs NUVL's 39.5% — a key indicator of consistent wealth creation.
| Metric | SMMTSummit Therapeuti… | NUVLNuvalent, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -2.1% | +1.5% |
| 1-Year ReturnPast 12 months | -29.4% | +53.5% |
| 3-Year ReturnCumulative with dividends | +784.0% | +171.2% |
| 5-Year ReturnCumulative with dividends | +194.7% | +446.1% |
| 10-Year ReturnCumulative with dividends | +91.6% | +446.1% |
| CAGR (3Y)Annualised 3-year return | +106.8% | +39.5% |
NUVL leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
NUVL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NUVL is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than SMMT's 1.89 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVL currently trades 90.6% from its 52-week high vs SMMT's 55.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SMMTSummit Therapeuti… | NUVLNuvalent, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.89x | 1.09x |
| 52-Week HighHighest price in past year | $30.98 | $113.02 |
| 52-Week LowLowest price in past year | $13.83 | $63.56 |
| % of 52W HighCurrent price vs 52-week peak | +55.4% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 42.2 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 3.5M | 544K |
NUVL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SMMT as "Buy" and NUVL as "Buy". Consensus price targets imply 41.0% upside for NUVL (target: $144) vs 24.4% for SMMT (target: $21).
| Metric | SMMTSummit Therapeuti… | NUVLNuvalent, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.33 | $144.40 |
| # AnalystsCovering analysts | 20 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVL leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallNuvalent, Inc. (NUVL)Leads 5 of 6 categories
Loading custom metrics...
SMMT vs NUVL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SMMT or NUVL a better buy right now?
Analysts rate Summit Therapeutics Inc.
(SMMT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SMMT or NUVL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +446. 1%, compared to +194. 7% for Summit Therapeutics Inc. (SMMT). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus SMMT's +91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SMMT or NUVL?
By beta (market sensitivity over 5 years), Nuvalent, Inc.
(NUVL) is the lower-risk stock at 1. 09β versus Summit Therapeutics Inc. 's 1. 89β — meaning SMMT is approximately 73% more volatile than NUVL relative to the S&P 500.
04Which is growing faster — SMMT or NUVL?
On earnings-per-share growth, the picture is similar: Nuvalent, Inc.
grew EPS -48. 9% year-over-year, compared to -364. 5% for Summit Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SMMT or NUVL?
Summit Therapeutics Inc.
(SMMT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Nuvalent, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMMT leads at 0. 0% versus 0. 0% for NUVL. At the gross margin level — before operating expenses — SMMT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SMMT or NUVL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SMMT or NUVL better for a retirement portfolio?
For long-horizon retirement investors, Nuvalent, Inc.
(NUVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), +446. 1% 10Y return). Summit Therapeutics Inc. (SMMT) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUVL: +446. 1%, SMMT: +91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SMMT and NUVL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.